AI Drug Discovery Is Not Just About Speed

AI in drug discovery is often framed as a speed story. Faster screening, faster structure prediction, faster candidate generation.

But speed is only the surface.

What AI really changes is the way search space is organized. In traditional drug discovery, much of the challenge lies not only in testing compounds, but in deciding where to look. AI expands the ability to navigate vast biological and chemical spaces, but it does not eliminate the underlying uncertainty of biology itself.

This matters because many public discussions confuse computational acceleration with biological validation. The former can improve dramatically. The latter remains slow, expensive, and path-dependent.

My view is that the long-term value of AI in biotech will depend less on whether it makes discovery “faster” in a general sense, and more on whether it improves the quality of search, prioritization, and decision-making under uncertainty.

Keywords: AI, Biotech, Drug Discovery, Search Space, Validation